Prolactin and psychopathology in schizophrenia: a literature review and reappraisal
- PMID: 24800074
- PMCID: PMC3985293
- DOI: 10.1155/2014/175360
Prolactin and psychopathology in schizophrenia: a literature review and reappraisal
Abstract
Secretion of the anterior pituitary hormone prolactin can be significantly increased by antipsychotic drugs, leading to a range of adverse effects in patients with schizophrenia. However, there is evidence from a variety of studies that prolactin may also be related to symptom profile and treatment response in these patients, and recent work has identified variations in prolactin secretion even in drug-free patients. In this paper, a selective review of all relevant studies pertaining to prolactin and schizophrenia, including challenge and provocation studies, is presented. The implications of this work are discussed critically. A tentative model, which synthesizes these findings and argues for a significant role for prolactin in the development of schizophrenia, is outlined.
References
-
- Kruger THC, Leeners B, Naegeli E, et al. Prolactin secretory rhythm in women: immediate and long-term alterations after sexual contact. Human Reproduction. 2012;27(4):1139–1143. - PubMed
-
- Ohta C, Yasui-Furukori N, Furukori H, et al. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(2):573–576. - PubMed
-
- Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Human Psychopharmacology. 2008;23(3):201–209. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
